SAGE Therapeutics Stock Lands Bull Note Ahead of Earnings

SAGE scored yet another upbeat analyst endorsement

Managing Editor
Aug 6, 2018 at 10:09 AM
facebook twitter linkedin


Biopharmaceutical concern SAGE Therapeutics Inc (NASDAQ:SAGE) popped higher out of the gate to peak at $149.47 in early trading, after Piper Jaffray initiated coverage on the stock with an "overweight" rating and $206 price target. The brokerage firm's price target implies expected upside of 41.4% upside to Friday's close at $145.68, and it's also north of SAGE's late-January record intraday peak of $195.97. 

SAGE Therapeutics stock has been trading mostly sideways since its early December post-earnings bull gap, and entered today's session with an 11.5% year-to-date deficit. However, the stock's 2018 lows have been contained by the $140 level.

Taking a broader view of analyst sentiment, all 12 of the brokerage firms covering SAGE stock sport "buy" or "strong buy" recommendations. This bullish sentiment is echoed by the stock's average 12-month price target of $208.86, which marks a 43.4% premium to last week's close -- roughly in line with Piper Jaffray's new forecast.

Elsewhere, short interest on SAGE rose by 6% during the past two reporting periods, and now represents nearly 9% of the stock's total available float. This supply of short interest represents about 11 times SAGE Therapeutics stock's average daily trading volume.

Looking ahead, SAGE is slated to report its second-quarter earnings before the market opens this Tuesday, Aug. 7. The drug name has ended higher the day after earnings in five of the past eight quarters, with an average single-day move of 4.8% regardless of direction. This time around, the options market is pricing in a steeper-than-usual 7% post-earnings move for SAGE.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

Schaeffer's Investment Research Master Portfolio Trial
 


 


 
Special Offers from Schaeffer's Trading Partners